Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients
Diffuse Large B-cell Lymphoma|Relapsed and Refractory
DRUG: Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
CR, Complete remission rate, according to Lugano 2014 criteria., Up to 36 months
ORR, Overall remission rate, according to Lugano 2014 criteria., Up to 36 months
PFS, Progression-free survival, Up to 36 months|OS, Overall survival, Up to 36 months
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients